Skip to main content

Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy

Research Grant
Duke Scholars

Administered By

Ophthalmology

Awarded By

Kato Pharmaceuticals, Inc

Start Date

October 15, 2019

End Date

December 31, 2021
 

Administered By

Ophthalmology

Awarded By

Kato Pharmaceuticals, Inc

Start Date

October 15, 2019

End Date

December 31, 2021